Orimmune discovered a new drug target called Δ42PD1 that regulates the immune system in a unique way, different from existing anti-cancer immunotherapies. By activating a special immune pathway, Δ42PD1 plays a critical role in diseases like HIV/AIDS and liver cancer. Prof. Chen's breakthrough unlocks the door to innovative immunotherapies, promising to transform patient care and create significant opportunities in the biotech market.
Prof. Zhiwei CHEN
Professor, Chair of Immunology & Immunotherapy
Suen Chi-Sun Professor in Clinical Science
AIDS Institute and Department of Microbiology
LKS Faculty of Medicine
Email: zchenai@hku.hk
After preclinical studies with promising protective results in animals, Orimmune has successfully obtained the first round of RAISe+ funding and local industry matching of about HK$ 220 million.
